Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|March 8, 2018
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI SubtrialSébastien Rinaldetti, Markus Pfirrmann, Kirsi Manz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Nature Medicine|November 13, 2020
Characterization of pre-existing and induced SARS-CoV-2-specific CD8<sup>+</sup> T cellsIsabel Schulien, Janine Kemming, Valerie Oberhardt, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsFelix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.Leukemia|December 21, 2023
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibKaterina Machova Polakova, Ali Albeer, Vaclava Polivkova, et al.Annals of Hematology|September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAlice Fabarius, Lida Kalmanti, Christian T Dietz, et al.NPJ Precision Oncology|June 29, 2026
Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysisMarie-Elisabeth Leßmann, Felix Carl Saalfeld, Lea Ruge, et al.Pageof 9